InMed Pharmaceuticals Reports Q3 Financial Results
- Financial Performance: InMed Pharmaceuticals reported a Q3 GAAP EPS of -$0.73, indicating challenges in profitability that could negatively impact investor confidence and stock performance.
- Cash Flow Status: As of March 31, 2026, the company's cash, cash equivalents, and short-term investments totaled $5.2 million, a significant decline from $10.8 million on June 30, 2025, highlighting increased liquidity risks that may limit future operational and R&D investments.
- Compliance Notice: InMed received a Nasdaq non-compliance notice, which poses a risk of delisting, potentially affecting the company's financing capabilities and market image, further exacerbating investor anxiety.
- Future Outlook: Given the current financial situation and compliance pressures, InMed Pharmaceuticals must implement effective measures to improve financial health, ensure ongoing operations, and restore market trust.
Trade with 70% Backtested Accuracy
Analyst Views on INM
About INM
About the author
InMed Pharmaceuticals Reports Q3 Financial Results
- Financial Performance: InMed Pharmaceuticals reported a Q3 GAAP EPS of -$0.73, indicating challenges in profitability that could negatively impact investor confidence and stock performance.
- Cash Flow Status: As of March 31, 2026, the company's cash, cash equivalents, and short-term investments totaled $5.2 million, a significant decline from $10.8 million on June 30, 2025, highlighting increased liquidity risks that may limit future operational and R&D investments.
- Compliance Notice: InMed received a Nasdaq non-compliance notice, which poses a risk of delisting, potentially affecting the company's financing capabilities and market image, further exacerbating investor anxiety.
- Future Outlook: Given the current financial situation and compliance pressures, InMed Pharmaceuticals must implement effective measures to improve financial health, ensure ongoing operations, and restore market trust.
InMed Pharmaceuticals Faces Nasdaq Warning Over Share Price
- Nasdaq Warning: InMed Pharmaceuticals received a notice from Nasdaq due to its shares trading below $1 for 30 consecutive trading days from February 11 to March 26, 2026, indicating significant market pressure and compliance risks for the company.
- Compliance Period: The company has a 180-day window to regain compliance by achieving a closing price above $1 for 10 consecutive days, a requirement that directly impacts its listing status on Nasdaq.
- Potential Actions: InMed may consider measures such as a reverse stock split to regain compliance, which not only aims to meet Nasdaq's requirements but could also influence investor confidence in the company's future prospects.
- Right to Appeal: InMed retains the right to appeal if it fails to meet the requirements, providing additional leeway despite the potential delisting risk, which may affect shareholder decisions and market reactions.
Intuit Shares Rise: 20 Stocks Making Moves in Premarket Trading
Intuit's Financial Performance: Intuit Inc. reported better-than-expected first-quarter results, with revenue of approximately $3.89 billion and adjusted earnings of $3.34 per share, leading to a 3.2% increase in share price during pre-market trading.
Second-Quarter Expectations: The company anticipates second-quarter revenue growth of 14% to 15% and adjusted earnings between $3.63 and $3.68 per share, which is below analyst estimates.
Pre-Market Stock Movements: Several stocks saw significant pre-market trading movements, including Nuvve Holding Corp, which surged 49.4%, and Enviri Corp, which gained 31.5% after announcing a major sale.
Declines in Other Stocks: Conversely, Pasithea Therapeutics Corp experienced a notable decline of 25.3% following the release of interim trial data, alongside other stocks like Safe & Green Holdings Corp and VisionSys AI Inc, which also saw significant drops.
Nvidia Shares Rise Over 5%; Check Out 20 Stocks Making Moves in Premarket Trading
NVIDIA's Strong Performance: NVIDIA Corp's shares rose 5.2% in pre-market trading after reporting a 62% year-over-year revenue increase to $57.0 billion for Q3, surpassing expectations with a strong revenue forecast for the current quarter.
Notable Gainers: Several stocks saw significant pre-market gains, including Sonder Holdings Inc (+138.8%), Inspire Veterinary Partners Inc (+60.3%), and Cerence Inc (+29.2%), following positive financial results or forecasts.
Major Losers: WeShop Holdings Limited experienced a sharp decline of 38.8% in pre-market trading after a previous surge, while other notable losers included Brera Holdings PLC (-35.5%) and Meihua International Medical Tech Co Ltd (-23.8%).
Market Overview: The pre-market trading session showed a mix of gains and losses across various stocks, with some companies reporting better-than-expected financial results while others faced significant declines.
What Factors Contributed to InMed's (INM) 22% Rise in After-Hours Trading?
Stock Performance: InMed Pharmaceuticals Inc. shares rose 21.98% in after-hours trading to $1.50, despite a 15.75% drop during the regular session, closing at $1.23.
Research Milestone: The company successfully completed pharmacokinetic studies for its Alzheimer’s candidate INM-901 in large animal models, demonstrating strong bioavailability and therapeutic exposure.
Regulatory Plans: InMed is preparing for Investigational New Drug (IND) submission by conducting dose-ranging studies and a pre-IND meeting with the FDA, alongside additional development for production scaling.
Financial Overview: As of September 30, InMed reported $9.3 million in cash, sufficient to fund operations into Q4 2026, although its stock has declined 74.38% this year, with a market cap of $3.45 million.
InMed Scheduled to Present at the Life Sciences Virtual Investor Forum on September 18, 2025
Event Announcement: InMed Pharmaceuticals Inc. will present at the Life Sciences Virtual Investor Forum on September 18, 2025, where CEO Eric A. Adams will discuss updates on the company's drug pipeline, including recent data on INM-901 for Alzheimer's treatment.
Interactive Participation: The event will allow real-time questions from investors, with an archived webcast available for those unable to attend live. Pre-registration is recommended for a smoother experience.
InMed Pharmaceuticals Reports Q3 Financial Results
- Financial Performance: InMed Pharmaceuticals reported a Q3 GAAP EPS of -$0.73, indicating challenges in profitability that could negatively impact investor confidence and stock performance.
- Cash Flow Status: As of March 31, 2026, the company's cash, cash equivalents, and short-term investments totaled $5.2 million, a significant decline from $10.8 million on June 30, 2025, highlighting increased liquidity risks that may limit future operational and R&D investments.
- Compliance Notice: InMed received a Nasdaq non-compliance notice, which poses a risk of delisting, potentially affecting the company's financing capabilities and market image, further exacerbating investor anxiety.
- Future Outlook: Given the current financial situation and compliance pressures, InMed Pharmaceuticals must implement effective measures to improve financial health, ensure ongoing operations, and restore market trust.
InMed Pharmaceuticals Faces Nasdaq Warning Over Share Price
- Nasdaq Warning: InMed Pharmaceuticals received a notice from Nasdaq due to its shares trading below $1 for 30 consecutive trading days from February 11 to March 26, 2026, indicating significant market pressure and compliance risks for the company.
- Compliance Period: The company has a 180-day window to regain compliance by achieving a closing price above $1 for 10 consecutive days, a requirement that directly impacts its listing status on Nasdaq.
- Potential Actions: InMed may consider measures such as a reverse stock split to regain compliance, which not only aims to meet Nasdaq's requirements but could also influence investor confidence in the company's future prospects.
- Right to Appeal: InMed retains the right to appeal if it fails to meet the requirements, providing additional leeway despite the potential delisting risk, which may affect shareholder decisions and market reactions.
Intuit Shares Rise: 20 Stocks Making Moves in Premarket Trading
Intuit's Financial Performance: Intuit Inc. reported better-than-expected first-quarter results, with revenue of approximately $3.89 billion and adjusted earnings of $3.34 per share, leading to a 3.2% increase in share price during pre-market trading.
Second-Quarter Expectations: The company anticipates second-quarter revenue growth of 14% to 15% and adjusted earnings between $3.63 and $3.68 per share, which is below analyst estimates.
Pre-Market Stock Movements: Several stocks saw significant pre-market trading movements, including Nuvve Holding Corp, which surged 49.4%, and Enviri Corp, which gained 31.5% after announcing a major sale.
Declines in Other Stocks: Conversely, Pasithea Therapeutics Corp experienced a notable decline of 25.3% following the release of interim trial data, alongside other stocks like Safe & Green Holdings Corp and VisionSys AI Inc, which also saw significant drops.
Nvidia Shares Rise Over 5%; Check Out 20 Stocks Making Moves in Premarket Trading
NVIDIA's Strong Performance: NVIDIA Corp's shares rose 5.2% in pre-market trading after reporting a 62% year-over-year revenue increase to $57.0 billion for Q3, surpassing expectations with a strong revenue forecast for the current quarter.
Notable Gainers: Several stocks saw significant pre-market gains, including Sonder Holdings Inc (+138.8%), Inspire Veterinary Partners Inc (+60.3%), and Cerence Inc (+29.2%), following positive financial results or forecasts.
Major Losers: WeShop Holdings Limited experienced a sharp decline of 38.8% in pre-market trading after a previous surge, while other notable losers included Brera Holdings PLC (-35.5%) and Meihua International Medical Tech Co Ltd (-23.8%).
Market Overview: The pre-market trading session showed a mix of gains and losses across various stocks, with some companies reporting better-than-expected financial results while others faced significant declines.
What Factors Contributed to InMed's (INM) 22% Rise in After-Hours Trading?
Stock Performance: InMed Pharmaceuticals Inc. shares rose 21.98% in after-hours trading to $1.50, despite a 15.75% drop during the regular session, closing at $1.23.
Research Milestone: The company successfully completed pharmacokinetic studies for its Alzheimer’s candidate INM-901 in large animal models, demonstrating strong bioavailability and therapeutic exposure.
Regulatory Plans: InMed is preparing for Investigational New Drug (IND) submission by conducting dose-ranging studies and a pre-IND meeting with the FDA, alongside additional development for production scaling.
Financial Overview: As of September 30, InMed reported $9.3 million in cash, sufficient to fund operations into Q4 2026, although its stock has declined 74.38% this year, with a market cap of $3.45 million.
InMed Scheduled to Present at the Life Sciences Virtual Investor Forum on September 18, 2025
Event Announcement: InMed Pharmaceuticals Inc. will present at the Life Sciences Virtual Investor Forum on September 18, 2025, where CEO Eric A. Adams will discuss updates on the company's drug pipeline, including recent data on INM-901 for Alzheimer's treatment.
Interactive Participation: The event will allow real-time questions from investors, with an archived webcast available for those unable to attend live. Pre-registration is recommended for a smoother experience.
